Dr. FAN Guohuang, President and CEO of Immunophage Biomedical Co., Ltd., is the chairman of our Board, the general manager and chief medical officer of our Company. Dr. Fan has more than 20 years of experience in biomedical research. From February 2001 to January 2002, he worked as a lecturer in the Department of Cancer Biology at Vanderbilt University. From May 2004 to April 2006 and subsequently from July 2006 to June 2008, he worked as an assistant professor at Vanderbilt University School of Medicine. Dr. Fan was appointed as an assistant professor in the department of biomedical sciences of Meharry Medical College in February 2006. He has served as the tenured associate professor in the department of neurobiology and neurotoxicology of Meharry Medical College since February 2008. He was appointed as an assistant professor in the department of pharmacology and toxicology at Virginia Commonwealth University School of Medicine in May 2008. From March 2010 to March 2016, he worked as an associate director at GlaxoSmithKline (Shanghai) R&D Co., Ltd. . He served as the deputy dean of the School of Translational Medicine and the director of the biomedical research centre of Nanchang University from April 2016 to July 2018.

Dr. Fan obtained his doctoral degree in nuclear medicine from Shanghai Jiao Tong University School of Medicine in 1996. Following his doctoral studies, he underwent six years of postdoctoral training at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences in the PRC, and then Vanderbilt University in the United States.

Dr. Fan is a renowned cancer biology and neurobiology expert, having published over 60 papers in peer-reviewed international journals and holding over 20 patents. His contributions have been recognised through various prestigious awards, including the National Natural Science Award (2002), the Chinese Medical Science Award (2001). He has also been honoured as a scholar of the 'One-hundred Talent Program' by the Chinese Academy of Sciences.

Dr. WANG Jian Fei is the Chief Scientific Officer of our Company. He is primarily responsible for the overall management of drug research and product development of our Group. Dr. Wang has more than 20 years of experience in the pharmaceutical industry. Dr. Wang was a researcher associate in abnormal wound healing and then an assistant professor in the division of plastic surgery, department of surgery, faculty of medicine & dentistry at the University of Alberta from April 2005 to July 2007 and from August 2007 to January 2010, respectively. From January 2009 to April 2018, he worked at GlaxoSmithKline (Shanghai) R&D Co., Ltd. , where his last position was a director of integrated bioscience platform department. From May 2018 to January 2019, he worked as a senior vice president at Hangzhou Qihan Bio Inc.

Dr. Wang obtained his bachelor of science's degree in veterinary medicine from Nanjing Agricultural University in the PRC in July 1988. He completed his postdoctoral residency in laboratory animal medicine at the University of Pennsylvania in the United States in July 1998. He further obtained his doctoral degree in tissue injury and repair from the University of Calgary in Canada in June 2003, and completed his post-doctoral fellowship in rheumatoid arthritis from Harvard Medical School in the United States in March 2005. 

Dr. Wang has been recognised as the Senior Laboratory Animal Veterinarian by China Laboratory Animal Association since August 2019 and he has been nominated as Entrepreneurship and Innovation Talents of Jiangsu Province in 2022. 

Ms. TAO Sha, is an executive Director, the vice president and the Board secretary and joint company secretary of our Company. She joined our Group in 23 April 2020 and was appointed as the vice president and board secretary of our Group in October 2024. She was appointed as a Director in April 2021 and was re-designated as an executive Director on 26 September 2025. She is primarily responsible for various critical aspects, including financial affairs, capital operation, human resources, administration, environment healthy safety and board secretarial matters of our Group. Ms. Tao is also the person in charge in relation to the financial affairs of our Company.

Ms. Tao is a member of the Remuneration Committee. Ms. Tao has more than 20 years of experience in capital operation and human resource management and board secretarial matters. Prior to joining our Group, Ms. Tao served as an assistant human resources manager of Shanghai SLAC Laboratory Animal Co., Ltd. from August 2004 to April 2020. Ms. Tao obtained her master of public administration degree from Shanghai Normal University in the PRC in January 2015.

Dr. Liu brings extensive expertise and knowledge in neurodegenerative diseases, with over 15 years of research experience. As the Supervisor and Head of the Neurology & Business Department, she is pivotal in overseeing preclinical pharmacology and efficacy studies in the neuroscience field.

Dr. Liu completed her Ph.D. at the Institute of Neuroscience, Chinese Academy of Sciences. After her doctoral studies, she pursued three years of postdoctoral training at the Shanghai Institutes for Biological Sciences. Before joining Immunophage, Dr. Liu served as a professor at Guangxi Medical University, where she gained four years of valuable work experience. Her research contributions were recognized through receiving two grants from the National Natural Science Foundation.

Head of our medicinal chemistry department, Dr. WANG Liugang, has 15 years of drug discovery experience across ChemPartner, MediChem, and Otsuka Pharmaceuticals, advancing pre-clinical candidates through strategic medicinal chemistry and translational science. 

He specialises in hit-to-lead optimisation, cost-efficient process development, and overcoming ADME/toxicity challenges in oncology, CNS, and metabolic disease pipelines.

His integrated drug discovery capabilities—from hit validation through preclinical candidate transition—consistently accelerate pipeline advancement through strategic resolution of complex translational barriers.

Head of the Antibody Drug Department, Mr. ZHENG Yuncheng, has long been dedicated to biopharmaceutical R&D, with deep expertise in antibody drugs and recombinant proteins, supported by a solid theoretical foundation and extensive practical experience. 

He specialises in the full development cycle of antibody therapeutics, including target screening, antibody discovery, antibody engineering, AI-assisted drug design, high-efficiency expression system development, and process development.

Mr. Li, as the executive Director and the director of the biology platform of our Group. Mr. Li joined our Group as a pharmacology researcher in February 2019 and then was promoted and served as the deputy director of the department of disease research and drug discovery from February 2022 to August 2024. He has served as the director of the biology platform since August 2024. He was appointed as a Director on 12 August 2024 and was re-designated as an executive Director on 26 September 2025. He is primarily responsible for project research and development, project management, department management, external technical communications and intellectual property protection.

Mr. Li has extensive experience in the pharmaceutical industry. Prior to joining our Group, Mr. Li worked as an intern researcher at Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences (formerly known as the Institute Pasteur of Shanghai, Chinese Academy of Sciences) from August 2017 to April 2018. From May 2018 to February 2019, he worked as a scientific research assistant at Life Sciences Institute Zhejiang University, responsible for project research and management of the laboratory.

Mr. Li obtained his bachelor of science degree in biotechnology from Northwest A&F University University in July 2014. He obtained his master's degree in biochemistry and molecular biology from Shanghai University in July 2017.

Our clinical operations director, Dr. HUANG Yongfeng, has over 20 years of experience leading phase 1 to phase 4 and NDA programs across therapeutic areas including autoimmune diseases, solid tumours, CNS disorders, cardio-metabolic conditions, and infectious diseases. He has successfully delivered more than 30 global and China-based clinical trials,  including 18+ non-oncology and 12+ oncology studies, managing over 100 CRCs and more than ten CRAs for multinational corporations. Expertise spans Investigator-Initiated Trials (IITs), Phases I-IV, and registration studies. Therapeutic areas include immunology, cardiovascular, endocrinology, anti-infectives, gastroenterology, solid tumors, and hematological malignancies.

Weiyun brings 16 years of expertise in new drug R&D project management and regulatory affairs, with deep knowledge and extensive experience in drug development and registration processes.

Holding a master’s degree from East China Normal University, Weiyun has built a distinguished career working with several renowned CROs and biotech companies. She has successfully led over 10 projects spanning oncology, autoimmune diseases, and CNS disorders, guiding them through R&D and registration processes into clinical Phase I/II trials.

Mr. HAO Zijun, is experienced with over five years in Marketing and Business Development across Immunology, Dermatology, CVD, CNS and Oncology. Holding a master's degree from the University of Hong Kong, Davis has established a distinguished career connection with MNCs, Big Pharma and Biotech companies. 

He is also skilled in R&D, Marketing, Strategic Planning, and Deal Structuring, with strong English communication skills for effective global collaboration.